• Wondering if Globus Medical at around US$92.76 is offering fair value or if the price is getting ahead of itself? This breakdown will help you frame that question using clear valuation checks.
• The stock has returned 1.5% over the past week, 5.2% over the last month, 6.3% year to date, 30.6% over 1 year, 59.8% over 3 years and 30.6% over 5 years, which may shape how you think about both upside potential and risk.
• Recent coverage of Globus Medical has focused on its role in the wider medical technology space and investor interest in the sector. This helps explain why the share price has been in focus and provides context when you weigh up whether the current price reflects expectations that are already built into the stock.
• Globus Medical currently scores 2 out of 6 on a simple undervaluation checklist. Next up is a closer look at traditional valuation approaches, followed by a more rounded way to think about what the stock might be worth.

Globus Medical scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Globus Medical Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and then discounting those back into today’s dollars using a required rate of return.

For Globus Medical, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $603.6 million. Analysts provide explicit forecasts out to 2027, with free cash flow for that year projected at $510.9 million, and Simply Wall St then extends those estimates further using its own assumptions.

Over a 10 year horizon, the projections run from $395.6 million in 2026 to $663.9 million in 2035, all in $. After discounting these projected cash flows back to today and adding a terminal value, the model arrives at an estimated intrinsic value of about $82.03 per share.

Compared with a recent share price of around $92.76, this implies Globus Medical screens as roughly 13.1% more expensive than the DCF estimate. This suggests the stock price reflects relatively optimistic expectations.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Globus Medical may be overvalued by 13.1%. Discover 58 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Globus Medical Price vs Earnings

For profitable companies, the P/E ratio is a useful shorthand because it links what you pay for each share to the earnings that the business is currently generating. It helps you judge how much investors are willing to pay for every dollar of profit.

What counts as a “normal” P/E depends on what investors expect for future growth and how much risk they see. Higher expected growth and lower perceived risk can support a higher P/E, while slower growth or higher risk usually aligns with a lower P/E.

Globus Medical is trading on a P/E of about 23.33x. That sits below the Medical Equipment industry average of roughly 25.80x and also below the peer group average of about 46.03x. Simply Wall St also calculates a proprietary “Fair Ratio” for Globus Medical of 22.40x, which is the P/E that might be expected given factors such as its earnings growth profile, industry, profit margins, market cap and risk characteristics.

This Fair Ratio can be more informative than a simple industry or peer comparison because it is tailored to the company’s own fundamentals rather than broad group averages. With the current P/E of 23.33x sitting modestly above the Fair Ratio of 22.40x, the stock screens as somewhat expensive on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Globus Medical Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story about Globus Medical to your numbers by linking your view of its products, margins and earnings to a forecast and then to a Fair Value that you can compare to the current share price. The tool sits inside the Community page and updates automatically when new news or earnings arrive. For example, one investor might build a more optimistic Globus Medical Narrative that lines up with a Fair Value around US$123 per share, while another takes a more cautious stance closer to US$90. You can see both side by side and decide which story best matches your own expectations before making any buy or sell decisions.

For Globus Medical however, we will make it really easy for you with previews of two leading Globus Medical Narratives:

Start with the bullish view, which aligns more closely with the higher analyst targets and a higher Fair Value. Then contrast it with a more cautious take that anchors nearer the low end of the range. Seeing them side by side can help you decide which one, if either, fits how you see the business.

Fair Value: US$123.00

Price gap vs Fair Value: about 24.6% below this narrative Fair Value

Revenue growth assumption: 8.55% a year

• Assumes margin expansion, manufacturing automation and integration benefits support higher earnings power than current consensus implies.
• Expects stronger adoption of technologies such as the Excelsius ecosystem and XR headset, with a larger mix of higher margin recurring software and disposables revenue.
• Uses a higher future P/E and analyst Fair Value of US$123 that would require confidence in revenue of about US$3.8b and earnings of about US$631.4m by 2029.

Fair Value: US$90.00

Price gap vs Fair Value: about 3.1% above this narrative Fair Value

Revenue growth assumption: 6.89% a year

• Assumes integration work, extended sales cycles and supply chain issues could weigh on how quickly margins and earnings progress.
• Flags pricing pressure, competition and reliance on surgical volumes as key risks to long run revenue and profit growth.
• Anchors on a Fair Value of US$90 that reflects lower assumed future P/E and a more cautious read on execution and earnings delivery through to 2028.

If you want to see how different investors stitch these numbers, risks and assumptions into a full story before making your own call on Globus Medical, the Community Narratives are the next place to go: See what the community is saying about Globus Medical.

Do you think there's more to the story for Globus Medical? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.